Method for treating pervasive development disorders
First Claim
Patent Images
1. A method of selecting an individual with a Pervasive Development Disorder (PDD) for treatment with a pharmaceutical composition comprising one or more digestive enzymes comprising:
- a. measuring a level of chymotrypsin in a fecal sample obtained from the individual, comprising detecting chymotrypsin in the fecal sample by photospectrometry;
b. identifying a patient to be treated as having a subnormal level of chymotrypsin; and
c. selecting the individual for treatment with a pharmaceutical composition comprising one or more digestive enzymes if the measured chymotrypsin level is subnormal.
2 Assignments
0 Petitions
Accused Products
Abstract
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.
217 Citations
11 Claims
-
1. A method of selecting an individual with a Pervasive Development Disorder (PDD) for treatment with a pharmaceutical composition comprising one or more digestive enzymes comprising:
-
a. measuring a level of chymotrypsin in a fecal sample obtained from the individual, comprising detecting chymotrypsin in the fecal sample by photospectrometry; b. identifying a patient to be treated as having a subnormal level of chymotrypsin; and c. selecting the individual for treatment with a pharmaceutical composition comprising one or more digestive enzymes if the measured chymotrypsin level is subnormal. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10)
-
-
2. A method of selecting an individual with a Pervasive Development Disorder (PDD) for treatment with a pharmaceutical composition comprising one or more digestive enzymes comprising:
-
a. measuring a level of chymotrypsin in a fecal sample obtained from the individual, comprising detecting chymotrypsin in the fecal sample by photospectrometry; b. selecting the individual for treatment with the pharmaceutical composition comprising one or more digestive enzymes if the measured chymotrypsin level is subnormal; and c. administering the pharmaceutical composition comprising one or more digestive enzymes if the individual is selected for treatment. - View Dependent Claims (11)
-
Specification